A Moscow cluster will participate in the industrial development of drugs in collaboration with an Indian company’s unit
Indian pharma major Hetero Labs has agreed with the city of Moscow to build a new plant and expand pharmaceutical collaboration in a special economic zone in the Russian capital.
A memorandum of cooperation was signed by Anatoly Garbuzov, Minister of the Moscow Government, and Murali Krishna Reddy, Director of Emerging Markets at Hetero Labs Limited, on the sidelines of the ongoing St. Petersburg International Economic Forum (SPIEF 2026).
“We believe that such a synergy between the city and foreign partners will help create the most promising, the most high-tech pharmaceutical drugs,” Garbuzov told RT.
He added that Moscow is one of the largest centers of pharmaceuticals and medical instrumentation in the country and more than 300 industry enterprises operate in the capital.
🇮🇳🇷🇺 A Dose Of Investment! One Of India’s Largest Pharma Firms Signs Deal For Moscow Production
At SPIEF, Moscow authorities signed a memorandum of intent with Hetero Labs on the implementation of a new industrial investment project.
Garbuzov, who is also the head of investment and industrial policy in Moscow, said the pharma industry in Russia’s capital is looking for international expertise. “India is really the world leader in the production of various pharmaceuticals.”
Sanjay Nayak, CEO of Makiz Pharma, a wholly owned unit of Hetero Labs, said his firm would set up a factory for producing oncological and other products.
The Moscow government has provided the land for the facility and offered incentives like tax rebates and assured buy-back of some pharma products, he said.
Hetero Labs produces active pharmaceutical substances and ready-made dosage forms for the treatment of HIV, hepatitis, cancer, and tuberculosis. Makiz already has a manufacturing facility in Moscow.
India plans to increase pharma exports to Russia, the Netherlands, and Brazil as New Delhi aims to expand its presence beyond the US, its largest market, due to tariff-related concerns, Reuters reported last September.
The Technopolis Moscow SEZ has 14 companies, 10 of which have already started production of drugs for the treatment of oncological, autoimmune, cardiological and other diseases.
Garbuzov also said the city is open to investment from the Indian electric car industry, and that a delegation of 18 Russian companies had visited India to explore market opportunities.
